D-VRD induction and autologous transplant in patients ≥70 years - Top-Institutions - MDSpire

D-VRD induction and autologous transplant in patients ≥70 years

  • By

  • Oren Pasvolsky

  • Curtis Marcoux

  • Denái R. Milton

  • Mark R. Tanner

  • Muhammad Bilal Islam

  • Qaiser Bashir

  • Samer Srour

  • Neeraj Saini

  • Paul Lin

  • Jeremy Ramdial

  • Yago Nieto

  • Guilin Tang

  • Yosra Aljawai

  • Asad A. Haider

  • Hans C. Lee

  • Krina K. Patel

  • Partow Kebriaei

  • Sheeba K. Thomas

  • Robert Z. Orlowski

  • Richard E. Champlin

  • Elizabeth J. Shpall

  • Muzaffar H. Qazilbash

  • June 5, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Hematology

  • #2

    Stanford
    Stanford

    Stanford, California

    Key Differentiators

    • Hematology

  • #3

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Hematology

Original Source(s)

D-VRD induction and autologous transplant in patients ≥70 years

  • by Oren Pasvolsky, Curtis Marcoux, Denái R. Milton, Mark R. Tanner, Muhammad Bilal Islam, Qaiser Bashir, Samer Srour, Neeraj Saini, Paul Lin, Jeremy Ramdial, Yago Nieto, Guilin Tang, Yosra Aljawai, Asad A. Haider, Hans C. Lee, Krina K. Patel, Partow Kebriaei, Sheeba K. Thomas, Robert Z. Orlowski, Richard E. Champlin, Elizabeth J. Shpall, Muzaffar H. Qazilbash

  • June 5, 2026

Related Content

Lymphocyte CD4/CD8 ratio predicts early immune-related toxicity in lung cancer patients treated with immune checkpoint inhibitors: a single-center retrospective study

Case report: A challenging case of stage IVB mixed neuroendocrine-non-neuroendocrine neoplasm of the gallbladder treated with extended radical resection including portal vein reconstruction

NAT10 as a central node in cancer biology: integrating epitranscriptomic regulation, metabolic reprogramming, and immune modulation